SBIR/STTR Research Award
A New Generation of Botulinum Toxin Vaccines
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INVENTOX INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned patients, this can include paralysis of the muscles of respiration, which can lead to death. A Presidential Blue Ribbon Panel has urged that medical countermeasures against the toxin be developed, including a vaccine against the toxin. There are 8 known serotypes of toxin (A to H), but only three of these account for almost all human illnesses (A, B, and E). Therefore, the Blue Ribbon Panel has proposed that highest priority be assigned to a trivalent A/B/E vaccine. Unfortunately, since the publication of the Panel's recommendations, there is not a single trivalent vaccine that has obtained regulatory approval. In
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients